Monthly archive | PharmaTutor

1 January 2020

Walk in interview in Production at Glenmark

Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with eight molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. Its subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs nearly 6000 people in over 80 countries.

Post : Sr. Officers / Officers / Jr. Officer - Production

1 January 2020

Career for M.Pharm, M.Sc in Vaccine Analytical Research Development at Panacea Biotec

Panacea Biotec is a leading research based Health Management Company, with an annual turnover of approx. Rs. 830 Crores. We are engaged in research, development, manufacture & marketing of Vaccines, Bio-Pharmaceuticals and Pharmaceuticals (Rx & OTC) of international quality and Health Services. All Panacea Biotec plants are accredited by international agencies and they follow current Good Manufacturing Practices, as per WHO guidelines.

Post : Executive - Vaccine Analytical Research Development

1 January 2020

Job for B.Pharm, B.Sc as Global Product Manager at Novo Nordisk

Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within Haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in more than 190 countries Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B).

Post : Global Product Manager

1 January 2020

Walk in interview in Production, Packing, Quality Control at Aurobindo Pharma

Aurobindo Pharma Ltd., is a Leading Pharmaceutical company having 23 plants worldwide with regulatory approvals from USFDA, UK MHRA etc. with a turnover of more than $2.5 billion dollars.

1 January 2020

Walk in interview in Production, Quality Control, Regulatory Affairs at Shilpa Medicare Limited

Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

Read more about FDA approves generic Febuxostat Tablets

Novadoz Pharmaceuticals, the U.S based sales & marketing affiliate for MSN Labs, based in Hyderabad India, has received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The product is AB rated to the brand Uloric©, marketed by Takeda Pharmaceuticals America, Inc. The company has commenced shipping of the product that is available in bottles of 30 tablets. Febuxostat brand and generic sales are trending over $430MIL over the previous 12 months according to recent published sales data.

(adsbygoogle = window.adsbygoogle || []).push({});

Read more about Janssen announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the completion of the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees, from XBiotech Inc., for $750 million. Should Janssen pursue bermekimab indications outside of dermatology, XBiotech may be eligible to receive additional payments upon the receipt of certain commercialization authorizations. Janssen Research & Development, LLC will develop bermekimab. The agreement was executed through Janssen Biotech, Inc. The transaction will be accounted for as a business combination.

Read more about A new breakthrough in developing effective antimalarial drugs

Parasites in the genus Plasmodium, which cause malaria, are transmitted to humans through bites from infected mosquitoes. The parasites manage to acclimatize to these two completely different hosts because the plasticity of their genome enables them to adapt as necessary. Scientists at the Institut Pasteur and the CNRS decided to investigate the epigenetic mechanisms behind this plasticity, in particular DNA methylation. They identified molecules capable of inhibiting DNA methylation and effectively killing even the most resistant Plasmodium falciparum parasites. The results of their research were published on November 27, 2019 in the journal ACS Central Science.

Search

January 2020

Walk in interview in Production at Glenmark

RECOMMENDED POSTS

Subscribe with us

Jobs by Category